Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer

• Published in: International journal of radiation oncology, biology, physics Vol. 98; no. 2; pp. 275 - 285
• Main Authors: Morris, W. James, Tyldesley, Scott, Rodda, Sree, Halperin, Ross, Pai, Howard, McKenzie, Michael, Duncan, Graeme, Morton, Gerard, Hamm, Jeremy, Murray, Nevin
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.06.2017
• Subjects: Age Factors; Aged; Aged, 80 and over; Androgen Antagonists - therapeutic use; ANDROGENS; BRACHYTHERAPY; Brachytherapy - methods; Combined Modality Therapy - methods; Disease-Free Survival; DOSES; EXTERNAL BEAM RADIATION THERAPY; Follow-Up Studies; Gonadotropin-Releasing Hormone - therapeutic use; GY RANGE 10-100; Hematology, Oncology and Palliative Medicine; Humans; Intention to Treat Analysis; Iodine Radioisotopes - therapeutic use; Kaplan-Meier Estimate; Lymphatic Irradiation - methods; Male; MEN; Middle Aged; NEOPLASMS; Pelvis; PROSTATE; Prostate-Specific Antigen - blood; Prostatic Neoplasms - blood; Prostatic Neoplasms - drug therapy; Prostatic Neoplasms - mortality; Prostatic Neoplasms - radiotherapy; Radiology; RADIOLOGY AND NUCLEAR MEDICINE; Radiotherapy Dosage; Re-Irradiation - methods; Re-Irradiation - statistics & numerical data; Time Factors

To report the primary endpoint of biochemical progression-free survival (b-PFS) and secondary survival endpoints from ASCENDE-RT, a randomized trial comparing 2 methods of dose escalation for intermediate- and high-risk prostate cancer. ASCENDE-RT enrolled 398 men, with a median age of 68 years; 69%...